NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO
STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2021 – 30.06.2021. The report is attached to this release and is also available on https://stenocare.com/investor-relations/
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
“Q2 brought clarity to the future of the medical cannabis industry in Denmark. The Danish Pilot Programme for treatment of patients was extended with another four-years, and cultivation/production is permanently legal. This is very good news for both patients and for the industry”
|Operating profit before depreciation (EBITDA)||-2,268||-2,867||-5,416||-5,493|
|Net financial items||-42||-586||-90||-1,503|
|Investments in tangible assets||552||129||2,964||6,737|
|Result per share (DKK)||-0.19||-0.29||-0.44||-0.60|
Result per share: The result for the period divided by the average number of shares. Total number of shares as of June 30, 2021, amounted to 11,676,126 (11,676,126). Average number of shares for the second quarter 2021 was 11,676,126 (9,853,883).
Solidity: Equity divided by total capital.
Highlights during the period
- In May 2021 – News that The Danish Parliament has decided to extend the Pilot Programme for medical cannabis, and also made Danish cultivation and production permanently legal
- May 2021 – STENOCARE held the Annual General Meeting
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on August 19, 2021.